Evolution of Zidovudine Resistance-Associated Genotypes in Human Immunodeficiency Virus Type 1-Infected Patients
- 1 May 1996
- journal article
- basic science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 12 (1) , 6-18
- https://doi.org/10.1097/00042560-199605010-00002
Abstract
Summary: Substantial differences have been described in the response of individual patients to zidovudine (ZDV) therapy, both in the clinical impact and in virus load. Genotypic changes associated with the appearance of drug resistance may also be different or occur at different rates. We have obtained the nucleotide sequence of the RT domain of individual HIV-1 genomes extracted from 10 plasma and peripheral blood mononuclear cell (PBMC) samples donated by two haemophiliac patients before, during, and after long-term ZDV therapy. Although the plasma virus load was similar throughout, the order and timing of appearance of resistance-associated substitutions differed in the two patients. In patient p74, K70R appeared after 4 months, T215Y at 5.5 months, and M41L at 13 months. In p87, K70R also appeared at 4 months, but T215Y and K219Q were not observed until 18 months and M41L not at all. Much greater sequence change overall occurred in p74. The evolution of the viral population in that patient was dominated by the unique appearance of T215Y and subsequently M41L, with all sequences from the last time point being descended by a single path from the pretreatment samples. However, in p87, several different lineages of RT sequences were found to persist throughout treatment. We propose that these differences in outcome may be determined by differences in genetic background at sites other than the five generally considered to be associated with ZDV sensitivity.Keywords
This publication has 20 references indexed in Scilit:
- HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapyThe Lancet, 1995
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistanceJournal of General Virology, 1994
- Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strainsJournal of General Virology, 1993
- Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.Proceedings of the National Academy of Sciences, 1993
- Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.Proceedings of the National Academy of Sciences, 1992
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentratesAIDS, 1991
- Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.Proceedings of the National Academy of Sciences, 1991
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989